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Abstract
Background: Previous psychological and pharmacological interventions have primarily focused on depression
disorders in populations with cardiovascular diseases (CVDs) and the efficacy of anxiety disorder interventions is
only more recently being explored. Transdiagnostic interventions address common emotional processes and the
full range of anxiety and depression disorders often observed in populations with CVDs. The aim of CHAMPS is to
evaluate the feasibility of a unified protocol (UP) for the transdiagnostic treatment of emotional disorders
intervention in patients recently hospitalized for CVDs. The current study reports the protocol of a feasibility
randomized controlled trial to inform a future trial.
Methods/Design: This is a feasibility randomized, controlled trial with a single-center design. A total of 50
participants will be block-randomized to either a UP intervention or enhanced usual care. Both groups will receive
standard CVD care. The UP intervention consists of 1) enhancing motivation, readiness for change, and treatment
engagement; (2) psychoeducation about emotions; (3) increasing present focused emotion awareness; (4)
increasing cognitive flexibility; (5) identifying and preventing patterns of emotion avoidance and maladaptive
emotion-driven behaviors (EDBs, including tobacco smoking, and alcohol use); (6) increasing tolerance of emotion-related
physical sensations; (7) interoceptive and situation-based emotion-focused exposure; and (8) relapse prevention strategies.
Treatment duration is 12 to 18 weeks. Relevant outcomes include the standard deviation of self-rated anxiety, depression
and quality of life symptoms. Other outcomes include intervention acceptability, satisfaction with care, rates of EDBs,
patient adherence, physical activity, cardiac and psychiatric readmissions. Parallel to the main trial, a nonrandomized
comparator cohort will be recruited comprising 150 persons scoring below the predetermined depression and anxiety
severity thresholds.
Discussion: CHAMPS is designed to evaluate the UP for the transdiagnostic treatment of emotional disorders targeting
emotional disorder processes in a CVD population. The design will provide preliminary evidence of feasibility, attrition,
and satisfaction with treatment to design a definitive trial. If the trial is feasible, it opens up the possibility for interventions
to target broader emotional processes in the precarious population with CVD and emotional distress.
Trial registration: ACTRN12615000555550, registered on 29/05/2015
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Background
Depression disorders are severely disabling and common
in cardiovascular disease (CVD) populations and portend
poorer cardiovascular outcome [1, 2] and high costs [3].
Consequently, the treatment of depression disorders has
dominated the contemporary psychological intervention
landscape in populations with CVD for the past 25 years.
Considering that depression is a putative CVD risk factor
that is also modifiable, a common hypothesis is that psy-
chosocial interventions in this population would lead to
significant benefits to an otherwise poorer cardiovascular
prognosis. However, prior intervention efforts addressing
depressive symptoms among CVD patients have not typic-
ally produced a sizeable clinical impact upon either depres-
sion or major CVD morbidity [4], and these unsatisfying
findings raise the question of how existing interventions
could be improved.
Several lines of evidence indicate that interventions fo-
cusing solely on depressive symptoms in CVD patients
may be too narrow in focus. Specifically, an accumulating
body of work shows that anxiety disorders confer CVD
morbidity risk independent of or in conjunction with de-
pression [5–14]. Indeed, the clinical reality of comorbid
depression and anxiety that is evident in CVD populations
[15] closely parallels findings in clinical and epidemio-
logical samples [16, 17]. Nonetheless, the heightened CVD
risk is not constrained to simply depression and anxiety
disorders given that positive associations between CVD
events have been reported in relation to hostility, anger,
stress, social isolation, worry, rumination, somatic depres-
sive symptoms, anxiety sensitivity, phobic anxiety and the
specific combination of negative affectivity and social in-
hibition [15, 18–22]. Collectively these findings point to
the likelihood that common processes underlying negative
emotions generally also portend CVD risk [19], raising the
possibility that an intervention that transcends diagnostic
boundaries and targets core emotional processes would be
a step toward improving mental health interventions
among CVD populations.
Limitations of the extant depression intervention findings
in CVD
Several lines of evidence raise the possibility that inter-
ventions focusing solely on depression disorders have
been ineffective in the population with CVDs. First,
prior controlled efforts to address depression in patients
with coronary artery disease [4, 23] and heart failure
[24] via psychological and pharmacological interventions
have reported only small, albeit significant, effects on de-
pression symptoms. Strikingly, the effect sizes for de-
pression symptom reduction are markedly smaller in
CVD samples than that observed in other chronic dis-
eases such as Type II diabetes samples [25]. Collective
findings have prompted a closer examination of the
specific therapeutic components of interventions for de-
pression used in CVD samples that might lead to an im-
proved outcome [26], as well as an exploration of novel
methods of mental health service delivery such as collab-
orative care [27]. Intriguingly, neither avenue of empir-
ical enquiry has consistently yielded moderate or larger
effect sizes for depression symptom reduction to date.
Likewise, despite initially promising findings from one
collaborative care randomized controlled trial (RCT)
suggesting a reduction in major adverse cardiac events
(MACE) [28], these findings were not sustained in the
longer term [23, 29]. Together, these findings point to
the strong possibility that mental health interventions
exclusively targeting depression in CVDs are incomplete
and too narrow in focus.
Anxiety burden and effects on CVD prognosis
Parallel to what has been reported for depression, an
emerging literature has uncovered an association be-
tween anxiety with CVD morbidity [8, 15], prompting
questions regarding whether depression is a discrete psy-
chiatric risk factor for MACE [11, 15]. Specifically, two
recent meta-analyses indicated that post-traumatic stress
disorder was associated with a twofold recurrent acute
coronary syndrome risk [7] whereas generalized anxiety
disorder (GAD) was associated with a 21 % increase in
MACE risk [15]. Although the association between panic
disorder and CVD events is tenuous [9, 30–34], panic
disorder nonetheless signifies high emergency depart-
ment utilization for chest pain and diagnostic tests to
rule out acute coronary syndromes [35], representing a
major burden on the healthcare system.
Importance of anxiety intervention in CVDs
Alongside depression, the American Heart Association [36]
and the German Cardiac Society [21] recommend compre-
hensive assessment of anxiety disorders in CVD patients.
In depressed CVD patients, the prevalence of comorbid
anxiety disorders is 30 % to 50 % [15, 27]. In addition, 50 %
of cardiac patients presenting for psychotherapy meet at
least one anxiety disorder diagnosis [37, 38], and higher
anxiety is associated with depression treatment resistance
[39]. Despite the prevalence of anxiety disorders in CVDs
exceeding community estimates [17] and comparable to
depression prevalence in CVD [15], no clinical guidelines
exist for treatment when anxiety disorder comorbidity is
present in this population [40]. Moreover, with increasing
recognition of the necessity to formulate interventions
matching the complexity of CVD populations [37, 41] and
the requirement for mental health interventions to match
transdiagnostic developments in clinical psychology
[42–47], the use of depression disorder-only treat-
ments may become increasingly obsolete.
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Previous work supporting the need for a transdiagnostic
approach in CVDs
Our recent work supports the assertion that an expan-
sion of mental health interventions beyond depression
to incorporate comorbid anxiety disorders is warranted
in populations with CVDs. A screen-and-treat model of
care for heart failure patients was undertaken in three
South Australian tertiary hospitals where we observed
that panic disorder and anxiety due to a medical condi-
tion was associated with high emergency department
utilization [48]. Furthermore, a reduction in CVD read-
missions was observed with CBT for GAD [49]. We hy-
pothesized that an intervention focusing on somatic
anxiety symptoms led to a significant reduction in CVD
hospital readmissions and to an improved depression re-
sponse [49].
Despite strong evidence collectively demonstrating how
anxiety disorders are common and necessitate treatment
in CVDs, a critical absence of interventions with broader
reach beyond depression exists, which forms a major
oversight in improving upon existing mental health inter-
ventions. Therefore, treatment of a broader range of emo-
tional disorders and their common emotional processes
likely would be an innovative step toward improving men-
tal health interventions and cardiovascular health among
CVD populations. Targeting the most common psycho-
logical processes that confer CVD risk with a single set of
therapeutic principles would open the possibility for a
more parsimonious application of effective mental health
interventions to a broader range of CVD patients. Herein,
we outline the methodology for a study of this type based
on the unified protocol (UP) for transdiagnostic treatment
of emotional disorders [42, 44–46].
Study objectives
The aim of the Cardiovascular Health in Anxiety and
Mood Problems Study (CHAMPS) is to prospectively
study the UP in patients with a recent CVD hospitalization
and comorbid depression and/or anxiety. The outcomes of
interest include the standard deviation of self-rated depres-
sion, anxiety and quality of life symptoms. Other relevant
outcomes include rates of EDBs (tobacco smoking and al-
cohol use), physical activity levels, patient adherence, car-
diac and psychiatric readmissions. A third objective is to
explore trajectories of emotional distress in relation to
EDBs and psycho-behavioral CVD risk factors. The data




This prospective study is a feasibility randomized con-
trolled trial, of parallel design, comparing the effective-
ness of the UP versus enhanced usual care. A total of 50
participants will be recruited from the Queen Elizabeth
Hospital, a tertiary hospital in the western urban area of
Adelaide, South Australia. Parallel to the main trial, a
nonrandomized comparator cohort will be recruited
comprising at least 150 persons scoring below the prede-
termined depression and anxiety severity thresholds.
Figure 1 depicts the trial design. The trial will be con-
ducted in accordance with the CONSORT statement [50].
Inclusion criteria
Inclusion criteria are as indicated below:
1. Age ≥ 18 years.
2. A primary hospital admission for CVD (specified by
relevant International Classification of Disease codes
for coronary artery disease, myocardial infarction,
heart failure, atrial fibrillation, other ventricular or
atrial arrhythmia, coronary revascularization
intervention, symptomatic coronary heart disease
including unstable angina pectoris, or heart valve
disease).
3. A MINI International Neuropsychiatric Interview
(MINI) diagnosis by randomization naïve assessors
of major depression, dysthymia, GAD, panic
disorder, agoraphobia, social anxiety/phobia, or
post-traumatic stress disorder.
4. Above the severity threshold for depression PHQ
scores (≥10) [51] or anxiety threshold GAD scores
(≥7) [52].
5. Fluency in English.
Exclusion criteria
Exclusion criteria include the following:
 A psychosis or bipolar disorder diagnosis
determined by medical history or randomization-
naïve assessors.
 High suicide risk at psychiatric interview.
 Observed cognitive impairment or dementia
impeding delivery of psychotherapy or ability to
provide informed consent.
 Neurodegenerative condition (for example,
Parkinson’s disease or multiple sclerosis)
 In receipt of GP, psychologist or psychiatrist
counselling elsewhere.
 A diagnosis of drug and alcohol dependence or
abuse determined by randomization-naïve assessors.
 Medical condition likely to be fatal within 1 year.
Nonrandomized comparator cohort
Participants scoring below the depression and anxiety se-
verity threshold on the PHQ-9 and GAD-7, and therefore
those without any distress, will be part of a nonrandomized
comparator cohort. The rationale for the comparator
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cohort is to answer empirical questions about EDBs,
incident emotional disorders and trajectories of emotional
distress. Several recent RCTs have adopted a similar ap-
proach and recruited a comparator cohort for observa-
tional purposes.
Non-randomized comparator cohort eligibility
1. Age ≥ 18 years.
2. A primary hospital admission for CVD (specified by
relevant International Classification of Disease codes
for coronary artery disease, myocardial infarction,
heart failure, atrial fibrillation, other ventricular or
atrial arrhythmia, coronary revascularization
intervention, symptomatic coronary heart disease
including unstable angina pectoris, or heart valve
disease).
3. Free from any MINI diagnosis by randomization-naïve
assessors of major depression, dysthymia, GAD, panic
disorder, agoraphobia, social anxiety/phobia, and
post-traumatic stress disorder.
4. Free from any MINI diagnosis by randomization-naïve
assessors or medical history of psychosis or
bipolar disorder.
5. Below the severity threshold for depression PHQ
scores (≤ 9) [51] or anxiety threshold GAD scores
(≤ 6) [52].
6. Fluency in English.
Proposed sample
The proposed sample for this study was 50 patients ran-
domized to the UP or EUC arm. Parallel to the RCT,
150 persons will be recruited into the nonrandomized
comparator cohort. In the total sample (N = 200), in-
corporation of the nonrandomized comparator cohort
(n = 150) and RCT participants (n = 50) will enable us to
explore the rates of EDBs, physical activity, medication
adherence, hospital readmission and feasibility of a
screen-and-treat model of care.
Planned statistical analysis
Data management is outlined elsewhere in our protocol.
Comparisons between UP, EUC and the nonrandomized
comparator cohort will be made at each follow-up time
point on patient level of satisfaction with aspects of psy-
chosocial care. We will evaluate whether screening, edu-
cation, and support in EUC is a suitable alternative to
UP. We will also monitor linkages with primary care to
Fig 1 Flow chart of CHAMPS participants through the study. CVD, cardiovascular disease; CHAMPS, Cardiovascular Health in Anxiety or Mood
Problems Study; EUC, enhanced usual care; GAD-7, generalized anxiety disorder-7; MINI, MINI International Neuropsychiatric Interview; PHQ,
Patient Health Questionnaire; UP, unified protocol
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determine whether our suicide risk management strategy
is viable when routine depression screening is imple-
mented. These data will help inform the design and day-
to-day running of a larger more definitive RCT. In terms
of feasibility, we will also evaluate the recruitment eligi-
bility, acceptance, and attrition rates, the length of time
taken to recruit, and compliance with the psychosocial
questionnaire battery.
In the total sample, incorporating the nonrandomized
comparator cohort, the association between EDBs, phys-
ical activity, and medication adherence with readmission
will be examined. Incident psychological distress and
distress trajectories will be evaluated in multi-level
models to provide a snapshot of different distress trajec-
tories on each of the measures used in CHAMPS. The
longitudinal changes in QOL will also be analyzed in the
same manner as incident psychological distress and dis-
tress trajectories described above.
Randomization
An independent statistician will generate the randomization
codes. Patients will be block randomized according to a
random number generator in alternating block sizes of
three and six. Allocation will be concealed in sequentially
numbered, opaque, sealed envelopes. Randomization will
be stratified by primary CVD admission (myocardial infarc-
tion, heart failure, atrial fibrillation, other ventricular or
atrial arrhythmia, coronary revascularization intervention,
symptomatic CHD including angina pectoris, and heart
valve disease) to obtain approximately equal sample sizes in
both groups.
Transdiagnostic unified protocol intervention
The UP is a transdiagnostic cognitive-behavioral inter-
vention explicitly designed to address the full range of
emotional disorders (anxiety, depressive, and related dis-
orders); this work is done by targeting core, underlying
emotional processes that lead to the development and
maintenance of symptoms across disorders. The UP is
designed for weekly and face-to-face delivery over 12 to
18 sessions. The UP consists of eight modules: (1) en-
hancing motivation for change and treatment engage-
ment, (2) facilitating better understanding of patients’
emotional experiences, (3) increasing present focused
emotion awareness, (4) increasing cognitive flexibility,
(5) identifying and preventing patterns of emotion avoid-
ance and maladaptive EDBs, (6) increasing awareness and
tolerance of emotion-related physical sensations, and (7)
interoceptive and situation-based emotion-focused expos-
ure, and (8) the final module is devoted to summarizing
the relevant techniques attained and to developing relapse
prevention strategies. A summary of the UP decision tree
and intervention outline is shown in Table 1. A more
complete description by Barlow et al. [53] can be found
elsewhere regarding the development of the UP and long-
term treatment outcomes. An experienced psychologist,
who is trained in the UP and trained by the research team
on CVDs, will deliver the intervention. In psychotherapy
intervention trials, blinding of the study participants, ther-
apists, and study coordinator is not possible. However, all
other members of the research team will remain blinded.
Intervention fidelity will be maintained by weekly supervi-
sion and monitored to determine if the UP requires modi-
fication in a larger trial among CVD patients.
Enhanced usual care
Patients randomized to the EUC group will receive an
education package delivered by the study coordinator
consisting of the beyondblue™ fact sheet regarding anx-
iety, depression, and coronary heart disease [54]. Partici-
pants and their general physician will be informed of the
baseline distress results and directed to available clinical
services (psychologist or psychiatrist), advising partici-
pants to seek assistance for achieving mental wellbeing
Table 1 A Description of the eight modules for the transdiagnostic unified protocol in the intervention group
Transdiagnostic unified protocol
Module Session Content
1. Preliminary module 1 Focusing on enhancing motivation and readiness for change and treatment
engagement
2. Psychoeducation 2 Educating patients on the nature of emotions and providing a framework for
understanding their emotional experiences
3. Present focused awareness 3 – 4 Increasing present focused emotion awareness
4. Cognitive flexibility 5 – 7 Increasing cognitive flexibility
5. Emotion-driven behaviors 8 – 11 Identifying and preventing patterns of emotion avoidance and maladaptive
emotion-driven behaviors
6. Emotion awareness and tolerance 12 - 15 Increasing awareness and tolerance of emotion-related physical sensations
7. Exposure 16 – 17 Interoceptive and situation-based emotion focused exposure
8. Summary 18 (or earlier if required) Summarizing the relevant techniques attained and developing relapse prevention
strategies.
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with the support of their general physician. This con-
forms to the National Heart Foundation of Australia’s™
guidelines [51, 55]. There are no restrictions on usual care.
Standard of care
All participants will receive standard medical care for CVDs
according to international guidelines regardless of the
study’s allocation. Standard CVD care includes referral to
cardiac rehabilitation, which includes a structured exercise
regime, and education about CVD risk factors such as
stress, dietary modifications and tobacco smoking cessation.
All study participants are permitted to seek psychopharma-
cology, which will be monitored, from outside the study.
Procedure
The potentially eligible patients are being identified at
the hospital 1 to 4 days after their CVD admission by an
authorized hospital staff member employed as a trial
coordinator in the cardiology department. A pool of
eligible participants will be determined by the trial coor-
dinator’s review of cardiology admissions and medical
records if required. In the first instance, persons will be
approached on the hospital ward by the trial coordinator
and provided with the study information sheet and an
opportunity to discuss any aspects of the study with the
trial coordinator. The potentially eligible patients are re-
contacted by the study’s trial coordinator by letter and
then telephone 2 to 8 weeks after their CVD admission.
Eligible and consenting participants will provide written
informed consent at the baseline appointment. Determin-
ation of the depression and anxiety thresholds will be
made at baseline. Randomization and patient allocation to
trial arms will take place by means of a random number
generator prepared in advance by an independent statisti-
cian offsite. All participants undergo active monitoring for
CVD events and mental well-being (PHQ-9 and GAD-7)
through a scheduled phone call every 4 to 6 weeks after
randomization. The numbers of eligible and successfully
recruited patients will be monitored and discussed on a
weekly basis between the CI and trial manager.
Patient rated measures
Psychosocial outcomes will be assessed with a battery of
fully validated measures at baseline, after the intervention
completion (12 to 18 weeks) and during the 6-month
follow-up period. The timing of assessments is shown in
Table 2. The self-rated measures will be collected to provide
the standard deviation of patient outcomes, which is neces-
sary to perform a power calculation in a larger more defini-
tive trial. Patient rates of alcohol and tobacco use, physical
activity, and hospital readmissions will be collected to pro-
vide an estimate for a larger more definitive trial.
Anxiety, depression and stress symptoms
Generalized anxiety symptoms will be measured by the 7-
item Generalized Anxiety Disorder scale (GAD-7). The
Table 2 Assessment schedule for participants through the study
Timing of assessment for all participants
Eligibility Pre-random ization 4 weeks 8 weeks 12 weeks 18 weeks 6 months
Variable Measure
Inclusion criteria
Depression PHQ-9 ✓ ✓ ✓ ✓ ✓ ✓
Generalized anxiety GAD-7 ✓ ✓ ✓ ✓ ✓ ✓
Psychiatric diagnosis MINI ✓ ✓ ✓
Post-eligibility
Anxiety severity OASIS ✓ ✓ ✓
General stress DASS-21 ✓ ✓ ✓
QOL SF-12 ✓ ✓ ✓
CVD outcome MACE ✓ ✓
Physical activity Exercise ✓ ✓ ✓
GATS Tobacco ✓ ✓ ✓
AUDIT-C Alcohol ✓ ✓ ✓
MOS SAS Adherence ✓
Psychiatric service, medication usage,
satisfaction with care
Self-report, audit ✓ ✓ ✓
AUDIT-C, Alcohol Use Disorders Identification Test-Shortened Clinical Version; CVD, cardiovascular disease; DASS-21, Depression, Anxiety Stress Scales; GAD-7,
Generalized Anxiety Disorder-7; GATS, Global Adult Tobacco Survey; MACE, major adverse cardiac event; MINI, MINI International Neuropsychiatric Interview; MOS
SAS, Medical Outcomes Study Specific Adherence Scale; OASIS, Overall Anxiety Severity And Impairment Scale; PHQ-9, Patient Health Questionnaire-9; SF-12,
Medical Outcomes Study Short Form-12; QOL, quality of life;
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GAD-7 severity threshold for clinically relevant symptoms
is a total GAD score ≥ 7 [52]. This questionnaire has fa-
vorable validity as a tool to identify depression and anxiety
disorders in medical patients [52]. The Overall Anxiety
and Severity Impairment Scale (OASIS) is a five-item brief
measure of anxiety symptoms, avoidance, and severity
used in a number of large RCTs [56]. Scores > 8 are indi-
cative of severe anxiety. Depression symptoms will be
measured by the 9-item Patient Health Questionnaire
(PHQ-9). The PHQ-9 severity threshold for clinically rele-
vant symptoms is a total PHQ score ≥ 10 [52]. Stress will
be measured by the Depression, Anxiety and Stress Scales,
a 21-item clinical measure commonly used in Australia,
validated in adults to age 90 years [57, 58], and in previous
studies in the cardiac surgery population [59, 60]. Mild
distress for the Stress scale is > 8.
Other rating scales
Quality of life will be assessed with the SF-12. The SF-12
is a commonly utilized and generalizable measure of
QOL in CVD populations [61, 62]. Other behavioral fac-
tors such as smoking and alcohol use are pertinent to
cardiovascular functioning and are likely to be EDBs tar-
geted by the UP intervention. Lifetime and current to-
bacco use will be measured by items from the Global
Adult Tobacco Survey [63]. Recent alcohol use will be
measured by the Alcohol Use Disorders Identification
Test-Shortened Clinical Version, which provides favor-
able sensitivity and specificity for the detection of prob-
lematic drinking [64]. The physical activity questions
from the Australian National Health Surveys are used to
classify participants as sedentary or having low, moder-
ate, or high levels of physical activity calculated with
metabolic equivalents [65].
Psychiatric disorders
The MINI is a brief structured interview that will be per-
formed by allocation-naïve assessors to determine the
primary psychiatric diagnosis and remission at the end
of the study [66, 67]. Assessment takes 20 to 40 minutes
to complete and has been validated among cardiac pa-
tients [68].
Medical and demographic data
Demographic, comorbidity and CVD condition data will
be obtained via project-specific questions. A statewide
hospital registry will be used to identify CVD and psy-
chiatric hospital admissions at 6-month follow-up. Major
CVD events include myocardial infarction, stroke, cor-
onary revascularization, cardiac failure, and arrhythmia
determined with relevant International Classification of
Disease Criteria Codes I00-I99 [69]. Admissions for pri-
mary psychiatric causes include suicide attempt, deliberate
self-harm, and panic disorder (International Classification
of Disease Criteria Codes F00-F99) [69]. Electronic data
linkage will be used to determine admissions, and adjudica-
tion of study outcomes will be performed by an independ-
ent panel of cardiologists, blinded to the randomization
arm. Patient confidentiality will be maintained.
Intervention acceptability and feasibility
Participants will be asked to rate how effective different
mental health care treatments were. The questions will as-
sess psychologist treatments (a component of CHAMPS)
and outside treatments: specifically, psychiatrist, GP coun-
selling, anti-depressant, anti-anxiety medications, and
other areas of support.
Stopping rules
If there are concerns about significant emerging psychi-
atric symptoms (for example, psychosis, mania or other
serious mental health conditions) associated with risks
to the participant or others, and particularly if the PHQ
score is ≥ 20 or the PHQ-9 item 9 score ≥ 2, the Mental
Health Triage will necessarily be contacted, or alterna-
tively, referral to an emergency department will be
undertaken if a risk is imminent and high. If significant
symptoms or comorbidities (for example, psychosis,
hypomania, or substance use) that do not meet the pre-
vious criteria emerge at any point during the study, the
psychologist will stop the study protocol, treat these
conditions and/or provide appropriate referral for psy-
chiatric or drug and alcohol service review. Psychiatric
referral should be considered if there are significant risk
factors for self-harm or CBT resistance such as personality
disorder, past self-harm attempts or treatment-resistant
depression.
Ethical considerations
The study has been approved by Human Research Ethics
Committee of The Queen Elizabeth Hospital (approval
#HREC/15/TQEH47). Written informed consent will be
obtained from the participants before inclusion. Study
participants are free to withdraw from the study at any
time. The study carries a suicide risk, and therefore, the
patients’ levels of suicidal ideation will be monitored
with the PHQ-9 (every 4 weeks). As in our real-world
clinic, we will follow a protocol for managing suicidal in-
tent and self-harm attempts [38]. An independent data
monitoring board will monitor adverse events (cardiac,
psychiatric, and other) and report these to the governing
ethics board. No plans are made to audit the conduct of
the trial until it is completed.
Discussion
The proposed feasibility RCT intervention for emotional
disorders will provide an innovative treatment that po-
tentially better aligns with the complex mental health
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needs for persons afflicted with CVDs. This is perhaps
the first investigation of its kind to comprehensively
treat a broad range of emotional disorders in CVDs util-
izing a single set of therapeutic principles. If the UP is
feasible and acceptable, we will develop a larger more
definitive trial, and therefore, the findings may hold rele-
vance for the design of future trials, healthcare service
delivery, and funding in cardiology.
Several limitations of this trial exist, including that it is
applied to multiple emotional disorders, and potential het-
erogeneity will exist in the study participants’ treatment
needs. In addition, the findings will require replication,
perhaps in larger numbers or more homogenous samples.
At the feasibility stage of intervention development,
the establishment of superiority of the UP from TAU is
important. Definitive identification of the specific com-
ponents of the active treatment that fosters change in
anxiety, depression, and quality of life among CVD pa-
tients will not be possible. Moreover, the length of
follow-up should be extended in a larger trial to deter-
mine the effects on CVD events.
The present feasibility RCT is designed to evaluate the
UP targeting emotional disorder processes in a CVD
population, with particular focus on acceptability, ac-
ceptance rates, satisfaction with care and attrition. If the
trial is viable, it opens up the possibility for interventions
to target broader emotional processes in the precarious
population with CVD and emotional distress and paves
the way for a larger more definitive trial. With increasing
recognition of the role of negative emotions in CVDs,
the need for depression disorder-only treatments could
become increasingly obsolete in CVDs as developments
in treatments match those in clinical psychology [46].
Trial status
The trial has been approved and is currently recruiting.
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